Potential treatment for polymorphic light eruption A 2010 phase III, randomized, double blind, placebo controlled, parallel group study was undertaken in Germany, the Netherlands, and Belgium to evaluate the safety and efficacy of subcutaneous implants of melanotan I (16 mg) in patients suffering from polymorphic light eruption (PLE), a condition characterized by a rash following exposure to sunlight
Since your body cant make 5-Amino-1MQ on its own, the only way to access this unique molecule is through specialized clinical protocols, typically delivered via injection or capsule, as part of a targeted longevity protocol supervised by healthcare professionals educated in these types of advanced metabolic and anti-aging therapies
Half of the samples contained the declared API, while half were incorrectly labeled, and the declared API was absent
Several research groups have found that, in animal models, silymarin and its components reduce and can even entirely prevent the kidney damage caused by these drugs (Bokemeyer 1996